Literature DB >> 7117793

Cholestyramine treatment reduces postprandial but not fasting serum bile acid levels in humans.

B Angelin, I Björkhem, K Einarsson, S Ewerth.   

Abstract

Fasting serum concentrations of cholic acid, chenodeoxycholic acid, and deoxycholic acid were determined in healthy subjects and in patients with familial hypercholesterolemia before and during treatment with cholestyramine. The bile acids were analyzed by a specific isotope-dilution technique by using gas chromatography-mass spectrometry. Cholestyramine treatment did not change the fasting concentration of total bile acids, but the contribution of cholic acid was increased; those of chenodeoxycholic acid and deoxycholic acid were decreased. No decrease of fasting bile-acid concentrations in portal venous serum was seen in 2 cholestyramine-treated gallstone patients. The postprandial total bile-acid concentration was about 40% lower during cholestyramine treatment in healthy subjects, reflecting a reduced postprandial inflow of bile acids to the liver. This degree of interruption of the postprandial enterohepatic circulation may be sufficient to produce a near maximal bile-acid biosynthesis rate and to promote lowering of plasma cholesterol also in the fasting state. It is concluded that the postprandial bile-acid inflow to the liver may be more important as a regulator of bile-acid biosynthesis than is the fasting level of bile acids.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7117793

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  8 in total

1.  Bile acid sequestrants: mechanisms of action on bile acid and cholesterol metabolism.

Authors:  K Einarsson; S Ericsson; S Ewerth; E Reihnér; M Rudling; D Ståhlberg; B Angelin
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953

Review 2.  Biosynthesis of bile acids in mammalian liver.

Authors:  S Kevresan; K Kuhajda; J Kandrac; J P Fawcett; M Mikov
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2006 Jul-Sep       Impact factor: 2.441

3.  Successful combination therapy--flunarizine, pentoxifylline, and cholestyramine--for spur cell anemia.

Authors:  K Aihara; H Azuma; Y Ikeda; M Akaike; M Abe; T Sugihara; T Matsumoto
Journal:  Int J Hematol       Date:  2001-04       Impact factor: 2.490

4.  Bile acid metabolism in hereditary forms of hypertriglyceridemia: evidence for an increased synthesis rate in monogenic familial hypertriglyceridemia.

Authors:  B Angelin; K S Hershon; J D Brunzell
Journal:  Proc Natl Acad Sci U S A       Date:  1987-08       Impact factor: 11.205

5.  Effect of ursodeoxycholic acid treatment on ileal absorption of bile acids in man as determined by the SeHCAT test.

Authors:  S Eusufzai; S Ericsson; T Cederlund; K Einarsson; B Angelin
Journal:  Gut       Date:  1991-09       Impact factor: 23.059

6.  Serum bile acids are higher in humans with prior gastric bypass: potential contribution to improved glucose and lipid metabolism.

Authors:  Mary-Elizabeth Patti; Sander M Houten; Antonio C Bianco; Raquel Bernier; P Reed Larsen; Jens J Holst; Michael K Badman; Eleftheria Maratos-Flier; Edward C Mun; Jussi Pihlajamaki; Johan Auwerx; Allison B Goldfine
Journal:  Obesity (Silver Spring)       Date:  2009-04-09       Impact factor: 5.002

7.  Effects of colesevelam HC1 on sterol and bile acid excretion in patients with type IIa hypercholesterolemia.

Authors:  J M Donovan; K Von Bergmann; K D R Setchell; J Isaacsohn; A S Pappu; D R Illingworth; T Olson; S K Burke
Journal:  Dig Dis Sci       Date:  2005-07       Impact factor: 3.487

8.  Bile acid toxicity in Paneth cells contributes to gut dysbiosis induced by high-fat feeding.

Authors:  Hui Zhou; Shi-Yi Zhou; Merritt Gillilland; Ji-Yao Li; Allen Lee; Jun Gao; Guanpo Zhang; Xianjun Xu; Chung Owyang
Journal:  JCI Insight       Date:  2020-10-15
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.